Pfizer is about to make a big push in cancer. Will investors listen?; Biotech launches with $82 million for Parkinson’s cell therapy

Taking stock of the drug industry, from the lab to the medicine chest

February 29, 2024 Check out STAT+

Sponsored By

By Ed Silverman Pharmalot Columnist, Senior Writer

Giannis Papanikos/AP STAT+ | Pfizer is about to make a big push in cancer. Will investors listen? In an interview, CEO Albert Bourla was insistent that investors are missing the potential of Pfizer's acquisition of Seagen. By Matthew Herper STAT+ | Biotech launches with $82 million for Parkinson's cell therapy The San Diego-based biotech plans to move into a clinical trial within the year for its lead drug candidate for people with Parkinson's. By Allison DeAngelis STAT+ | This chemist's last startup sold for $4 billion. Now investors have poured $173 million into her next act Jean Cui's new company is preparing to start clinical studies of potential medicines that could someday treat blood cancer and lung cancer. By Matthew Herper LISELOTTE SABROE/Scanpix/AFP via Getty Images STAT+ | A 'vaccine-like' version of Wegovy is on the drawing board at Novo Nordisk Novo Nordisk wants to develop obesity drugs with longer-lasting weight loss effects than existing treatments Wegovy and Zepbound. By Elaine Chen

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Pharmalot? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2024, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser